New HIV remission strategy combines vaccine, antibody, and drug – but trial pulled before start

NCT ID NCT03619278

Terminated Disease control Sponsor: Judit Pich Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study aimed to see if a personalized RNA vaccine, a powerful antibody (10-1074), and a drug called romidepsin could help people with HIV stop their daily antiretroviral pills while keeping the virus under control. The trial planned to enroll 56 adults with well-controlled HIV. However, the study was withdrawn before any participants were enrolled, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: personalized RNA vaccine (HIVACAR01), broadly neutralizing antibody (10-1074), and romidepsin
What this could lead to: If successful, this approach could allow people with HIV to stop daily antiretroviral therapy and maintain undetectable viral levels, pointing toward a functional cure.
What could go wrong: This trial was withdrawn before enrolling any participants, so no data exist. The combination therapy may cause severe side effects or fail to control the virus, and participants would still need lifelong monitoring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

More trials for these conditions

Other studies related to the condition(s) this trial covers.